Explore the vast range of titles available.

High-entropy materials (HEMs) constitute a revolutionary class of materials that have garnered significant attention in the field of materials science, exhibiting extraordinary properties in the realm of energy storage. These equimolar multielemental compounds have demonstrated increased charge capacities, enhanced ionic conductivities, and a prolonged cycle life, attributed to their structural stability. In the anode, transitioning from the traditional graphite (372 mAh g−1) to an HEM anode can increase capacity and enhance cycling stability. For cathodes, lithium iron phosphate (LFP) and nickel manganese cobalt (NMC) can be replaced with new cathodes made from HEMs, leading to greater energy storage. HEMs play a significant role in electrolytes, where they can be utilized as solid electrolytes, such as in ceramics and polymers, or as new high-entropy liquid electrolytes, resulting in longer cycling life, higher ionic conductivities, and stability over wide temperature ranges. The incorporation of HEMs in metal–air batteries offers methods to mitigate the formation of unwanted byproducts, such as Zn(OH)4 and Li2CO3, when used with atmospheric air, resulting in improved cycling life and electrochemical stability. This review examines the basic characteristics of HEMs, with a focus on the various applications of HEMs for use as different components in lithium-ion batteries. The electrochemical performance of these materials is examined, highlighting improvements such as specific capacity, stability, and a longer cycle life. The utilization of HEMs in new anodes, cathodes, separators, and electrolytes offers a promising path towards future energy storage solutions with higher energy densities, improved safety, and a longer cycling life.

High‐entropy materials (HEMs) represent a revolutionary class of materials that have garnered significant attention in the field of materials science due to their extraordinary properties in diverse fields of applications such as catalysis and electrochemistry. The past decade has witnessed a substantial increase in the study of these materials, exploring new synthesis routes and compositions. What began as the synthesis of high‐entropy alloys has expanded to encompass several classes of HEMs such as oxides, hydroxides, sulfides, nitrides, and carbides, among others. Several synthesis methods have been developed to produce these materials. This review therefore highlights the fundamental concepts of HEMs, including their core effects, with a major emphasis on their scalable synthesis routes. The advantages and drawbacks of these methods are also discussed. As HEMs transition from the lab to large‐scale production, there is a growing need for cost‐effective and scalable synthesis methods with high material yield suitable for a variety of applications like hydrogen storage, catalysis, batteries, supercapacitors, and fuel cells. Hence, this review serves as an introduction to scalable synthesis routes based on crystal structure, desired elements, synthesis times, and equipment costs. High‐entropy materials (HEMs) represent a new shift in material design for applications across a wide variety of fields, including energy storage, catalysis, biomedicine, water filtration, and coatings. Despite their potential, their large‐scale use has been constrained by material yields. This review focuses on scalable synthesis techniques for HEMs so that they can be utilized to a greater extent.

Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis. A genetic-based diagnostic test was designed to identify patients with an increased likelihood of response. We randomly assigned patients with glucocorticoid dependence or failure of conventional or advanced therapies for ulcerative colitis to receive intravenous tulisokibart (1000 mg on day 1 and 500 mg at weeks 2, 6, and 10) or placebo. Cohort 1 included patients regardless of status with respect to the test for likelihood of response. Cohort 2 included only patients with a positive test for likelihood of response. The primary analysis was performed in cohort 1; the primary end point was clinical remission at week 12. Patients with a positive test for likelihood of response from cohorts 1 and 2 were combined in prespecified analyses. In cohort 1, a total of 135 patients underwent randomization. A significantly higher percentage of patients who received tulisokibart had clinical remission than those who received placebo (26% vs. 1%; difference, 25 percentage points; 95% confidence interval [CI], 14 to 37; P<0.001). In cohort 2, a total of 43 patients underwent randomization. A total of 75 patients with a positive test for likelihood of response underwent randomization across both cohorts. Among patients with a positive test for likelihood of response (cohorts 1 and 2 combined), clinical remission occurred in a higher percentage of patients who received tulisokibart than in those who received placebo (32% vs. 11%; difference, 21 percentage points; 95% CI, 2 to 38; P = 0.02). Among all the enrolled patients, the incidence of adverse events was similar in the tulisokibart and placebo groups; most adverse events were mild to moderate in severity. In this short-term trial, tulisokibart was more effective than placebo in inducing clinical remission in patients with moderately to severely active ulcerative colitis. (Funded by Prometheus Biosciences, a subsidiary of Merck; ARTEMIS-UC ClinicalTrials.gov number, NCT04996797.).

Abstract Therapeutic drug monitoring (TDM) is the measurement of drug and antidrug antibody concentrations in individuals to guide treatment decisions. In patients with Crohn disease (CD), TDM, used either reactively or proactively, is emerging as a valuable tool for optimization of tumor necrosis factor (TNF) antagonist therapy. Reactive TDM is carried out in response to treatment failure, whereas proactive TDM involves the periodic monitoring of patients responding to TNF antagonist therapy to allow treatment optimization. In patients with CD, most of the available data for TDM relate to the first-to-market TNF antagonist infliximab and, to a lesser extent, to adalimumab and certolizumab pegol. Several gastroenterology associations, including the American Gastroenterology Association, have endorsed the use of reactive TDM in patients with active CD. However, fewer recommendations currently exist for the use of proactive TDM, although several new prospective randomized controlled trials evaluating proactive TDM strategies have been published. In this review, the current evidence for reactive and proactive TDM is discussed, and a proactive treatment algorithm for certolizumab pegol based on previously published threshold concentrations is proposed.